Connect
To Top

Researchers Have Discovered Cure for Alzheimer’s, And It Might be Lurking in Your Kitchen Cabinet!

A few years back, Rebecca Branchman, entrepreneur and neuroscientist, chanced upon a game-changing psychiatry discovery, or so she thought.

While doing some research on mice, she discovered that one very cheap drug could prevent mental health conditions such as PTSD and depression. You’d be over the moon as much as she was, wouldn’t you?

Mental health conditions plague millions in America and around the world, and the discovery of a cheap preventive drug by the neuroscientist had all the hallmarks of a success story.

 

Mental health conditions plague millions across the globe

Not Interested

Unfortunately, investors in the pharmaceutical industry weren’t interested in her discovery. Sad, right? But looking at it from their perspective, investors are in it for the money, and a cheap drug may not provide the returns they seek.

All the same, there’s always a solution to just about everything, and Branchman may have just found one to her conundrum. Partnering with Helena (the think tank) and other notable figures in the industry such as Mark McClellan, former FDA commissioner, there’s suddenly some light at the end of the tunnel.

With backing from these two, Branchman has already started attracting potential investors, with Dave Morin hopefully being the first of many that will jump onto the neuroscientist’s bandwagon.

Speaking to Business Insider, Helena’s project director Lyn Stoler admitted that pursuing this avenue would be beneficial to the population both financially and health-wise. The massive potential in the mass production of a cheap drug that prevents the onset of mental health issues cannot be underrated, given how much the world has suffered due to complications brought on by these conditions.

Former FDA commissioner Mr. McClellan is on board

 

So, why is it that investors weren’t so much into Branchman’s idea at first? Well, the fact is the scientist had no patent or anything protecting her research as personal intellectual property, and that she was using drugs already in the market meant the possibility of her work receiving a patent was minimal.

With her partnership with Helena, however, they are coming up with a financial mechanism to circumnavigate existing bottlenecks. You do know that a single drug can treat multiple diseases, right? This is the same argument that they are going with, claiming that although these drugs have long been on sale, they’ve never been used as mental health preventive drugs.

What’s more, Branchman would have to alter them slightly, a process referred to as drug repurposing, so that they can effectively work as she intends them to. This could be enough grounds for recognition as intellectual property, don’t you think?

Helena insists that pursuing this avenue would be beneficial to the general population

 

Research Institutions

And even if it isn’t recognized as such, Helena proposes that the research be done by either the government or academic research institutions, with private investors chipping in. When the drugs eventually hit the market and become a success, investors will get the full value of whatever amount they put in and then some.

The think tank has all this figured out; they’re only waiting for the government to play ball. The fact that drug repurposing takes between 3-5 years makes them confident that they’ll land themselves a deal, especially since developing traditional drugs takes 10 years at the very least. They also think that repurposed drugs could be used to treat MS, Alzheimer’s, and concussions.

More inMedicare

You must be logged in to post a comment Login